A Phase I, Open-Label Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously as a Single Agent or in Combination With Chemotherapy in Chinese Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Gastric cancer; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms IMYO29233
- Sponsors Roche
- 03 Jan 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2022 Planned End Date changed from 30 Jun 2022 to 31 Dec 2022.
- 14 Feb 2022 Planned End Date changed from 30 Sep 2021 to 30 Jun 2022.